Clinical trials: Membranous Glomerulonephritis
Membranous Nephropathy - PLA2R Induced
Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy
This exploratory study aims to assess the efficacy, safety of the experimental treatment based on a combination of rituximab (RTX), intravenous (IV) cyclophosphamide (CYC), and corticosteroids (S) administrated at lower…
- Trial name
- NCT05679336
- Testing
- Rituximab, Cyclophosphamide, and Corticosteroids
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Membranous Nephropathy - PLA2R Induced
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study
Objective: To assess the disappearance rate (half-life) of anti-PLA2R antibodies in high-risk primary membranous nephropathy (pMN) patients treated with obinutuzumab (OBI), and to evaluate immunological and clinical remission…
- Trial name
- NCT07163611
- Testing
- Obinutuzumab administration
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Efficacy and Safety
Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial
1. Main purpose: To evaluate the efficacy and safety of rituximab combined with tacrolimus in the treatment of intermediate and high-risk primary membranous nephropathy 2.
- Trial name
- NCT05532111
- Testing
- Rituximab combined with tacrolimus induction + rituximab maintenance, Rituximab combined with tacrolimus induction + tacrolimus maintenance, Glucocorticoid combined with cyclophosphamide induction + maintenance
- Volunteers
- 60 people
- Sponsor
- RenJi Hospital
SLE, Lupus Nephritis
Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis
In this comparative open-label cohort study, the investigators compared the efficacy and safety of tacrolimus (TAC)and cyclophosphamide (CYC) in the treatment of diffuse proliferative and membranous lupus nephritis with severe…
- Conditions
- SLE, Lupus Nephritis, Renal Insufficiency, End-stage Renal Disease
- Trial name
- NCT01207297
- Testing
- Tacrolimus, cyclophosphamide
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Primary Membranous Nephropathy
A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy
This study was divided into two stages. In the first stage (Phase Ib), 30 subjects were randomly divided into MIL62 600mg, MIL62 1000mg and cyclosporine groups at a ratio of 1:1:1, with 10 subjects in each group.
- Trial name
- NCT05398653
- Testing
- MIL62, Cyclosporine
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Hyperspectral Imaging, Idiopathic Membranous Nephropathy
Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN
Investigators propose hyperspectral imaging analysis as a method to distinguish the efficacy of hormone-combined cyclophosphamide therapy for PMN, and classify sensitive and insensitive patients treated with hormone-combined…
- Conditions
- Hyperspectral Imaging, Idiopathic Membranous Nephropathy, Cyclophosphamide
- Trial name
- NCT05850845
- Testing
- Microscopic hyperspectral imaging system
- Volunteers
- 40 people
- Sponsor
- Qianfoshan Hospital
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Lupus Nephritis
Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis
The objective of this study is to assess the as efficacy of rituximab as induction therapy in membranous lupus nephritis. Safety and tolerability will additionally be assessed.
- Trial name
- NCT00908986
- Testing
- Rituximab
- Sponsor
- Northwell Health
IgA Nephropathy, Membranous Nephropathy
IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients
IM19 CAR-T cell therapy for IgA nephropathy patients with urinary protein and renal dysfunction, as well as patients with intermediate to high-risk primary membranous nephropathy
- Trial name
- NCT06690359
- Testing
- IM19 chimeric antigen receptor T cell injection
- Volunteers
- 12 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Idiopathic Membranous Nephropathy
Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)
The trial is a random, open, control and monocentric trial. Mainly to assess the urine protein remission rate of tacrolimus (TAC) monotherapy for idiopathic membranous nephropathy (IMN).
- Trial name
- NCT03549663
- Testing
- Tacrolimus, Prednisone
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Nephrotic Syndrome, Membranous Nephropathy
Circulating Factors in Nephrotic Syndrome
A prospective observational study to investigate the treatment-associated changes of circulating factors associated with glomerular diseases among patients with de novo nephrotic syndrome admitted to hospital for a kidney biopsy.
- Conditions
- Nephrotic Syndrome, Membranous Nephropathy, Minimal Change Disease, Primary Focal Segmental Glomerulosclerosis
- Trial name
- NCT06315504
- Testing
- Observation
- Volunteers
- 104 people
- Sponsor
- Iain Bressendorff
Idiopathic Membranous Nephropathy
Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy
The purpose of this study is: To explore the potential role of tacrolimus in the treatment of membranous nephropathy. To investigate the safety and tolerability of tacrolimus vs methylprednisolone plus cyclophosphamide.
- Trial name
- NCT00302523
- Testing
- Tacrolimus
- Where
- 2 sites in China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nanjing University School of Medicine
Kidney Diseases, Chronic, Glomerular Diseases
Model Development and Application Based on Renal Pathology Images
This single-center retrospective observational cohort study will utilize digital renal pathology images along with corresponding clinical and laboratory data from patients who underwent kidney biopsy at Union Hospital, Tongji…
- Conditions
- Kidney Diseases, Chronic, Glomerular Diseases, Tubulointerstitial Kidney Diseases, IgA Nephropathy (IgAN)
- Trial name
- NCT07816874
- Where
- China
- Volunteers
- 8,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Glomerulonephritis, Membranous
Mycophenolate Mofetil in Membranous Nephropathy
Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for end-stage renal disease (ESRD). Treatment with cyclophosphamide is currently used as a treatment modality.
- Trial name
- NCT00135967
- Testing
- mycophenolate mofetil orally 1000 mg twice a day (BID), prednisone 0,5 mg/kg orally on alternate days, intravenous (i.v.) methylprednisolone 1000 mg, total 9
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Primary Membranous Nephropathy
Study of YK012 in Primary Membranous Nephropathy
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (PMN).
- Trial name
- NCT06982729
- Testing
- YK012
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Excyte Biopharma Ltd
Membranous Nephropathy
Autoreactive B Cells in Membranous Nephropathy
Membranous nephropathy (MN) is the most frequent cause of nephrotic syndrome (NS) in adults. The majority of MN patients show detectable circulating antibodies against the M-type phospholipase A2 receptor (PLA2R).
- Trial name
- PEPTIDE (NCT04095156)
- Testing
- In vitro assays.
- Where
- Italy
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Membranous Nephropathy
Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy
This is a non-pharmacological interventional monocentric study to primarily assess the levels of circulating phospholipase A2 receptor (PLA2R)-specific B cells in patients with PLA2R-mediated MN enrolled in the ORION and MONET…
- Trial name
- DEEPER (NCT06994468)
- Testing
- Flow-cytometry tetramer-based antigen-bait assay
- Where
- Italy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Membranous Nephropathy, Lupus Nephritis (LN)
Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy
This study is a single-arm, single-center, open-label, dose-escalation exploratory clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of CD19 CAR-γδ T cells.
- Conditions
- Membranous Nephropathy, Lupus Nephritis (LN), IgA Nephropathy (IgAN)
- Trial name
- NCT07535138
- Testing
- CD19 CAR-γδ T cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Air Force Military Medical University, China
Idiopathic Membranous Nephropathy
Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy
The Membranous Nephropathy is one of the most common cause of Nephrotic Syndrome of adults. In 2/3 of patients the cause of the disease is idiopathic.
- Trial name
- GEMRITUX (NCT01508468)
- Testing
- symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin), experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Refractory Membranous Nephropathy
Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy
This study is a single-center, prospective, exploratory Phase I clinical trial initiated by the team led by Associate Professor He Lijie from the Department of Nephrology, Xijing Hospital.
- Trial name
- NCT07266181
- Testing
- All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.
- Where
- China
- Volunteers
- 5 people
- Sponsor
- The First Affiliated Hospital of Air Force Medical University